Ventricular fibrillation following adenosine therapy for supraventricular tachycardia in a neonate with concealed Wolff-Parkinson-White syndrome treated with digoxin

Pediatr Emerg Care. 1995 Aug;11(4):238-9. doi: 10.1097/00006565-199508000-00013.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenosine / adverse effects*
  • Adenosine / therapeutic use
  • Anti-Arrhythmia Agents / adverse effects
  • Anti-Arrhythmia Agents / therapeutic use*
  • Cardiovascular Agents / adverse effects*
  • Cardiovascular Agents / therapeutic use
  • Contraindications
  • Digoxin / adverse effects
  • Digoxin / therapeutic use*
  • Drug Interactions
  • Humans
  • Infant, Newborn
  • Tachycardia, Supraventricular / chemically induced
  • Tachycardia, Supraventricular / drug therapy*
  • Ventricular Fibrillation / chemically induced*
  • Wolff-Parkinson-White Syndrome / drug therapy*

Substances

  • Anti-Arrhythmia Agents
  • Cardiovascular Agents
  • Digoxin
  • Adenosine